Sanofi-aventis Advances Diabetes Pipeline
By Staff Editor
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 2 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1362 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi-aventis has agreed to pay up to US$375 M to Metabolex to license a novel oral therapy in Phase II development for the treatment of type 2 diabetes, MBX-2982...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS